Want to see PYYX full AI Analyst Report?
Top Page
Pyxus International
(OTC:PYYX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.00
▼(-4.15% Downside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial quality—high leverage, thin equity, and negative operating/free cash flow alongside a sharp TTM revenue decline. Valuation is a key offset with a very low P/E, while technicals remain weak-to-neutral (below 20/50-day averages with negative MACD). The latest earnings call provides some support via reaffirmed guidance and improving credit metrics, but refinancing uncertainty and softer YoY sales keep risk elevated.
Positive Factors
EBITDA and Leverage Improvement
Higher rolling EBITDA and lower leverage indicate improved operating performance and debt capacity. If sustained, this can strengthen creditor confidence and reduce financial strain, although leverage remains elevated.
Negative Factors
High Leverage and Refinancing Risk
Very high leverage leaves limited balance-sheet flexibility and increases sensitivity to earnings or working-capital setbacks. Upcoming maturities add refinancing dependence, potentially diverting cash from investment and operations if unresolved.
Read all positive and negative factors
Positive Factors
Negative Factors
EBITDA and Leverage Improvement
Higher rolling EBITDA and lower leverage indicate improved operating performance and debt capacity. If sustained, this can strengthen creditor confidence and reduce financial strain, although leverage remains elevated.
Read all positive factors
Pyxus International (PYYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.02M
Dividend YieldN/A
Average Volume (3M)3.30K
Price to Earnings (P/E)3.3
Beta (1Y)-0.26
Revenue Growth-0.56%
EPS GrowthN/A
CountryUS
Employees3,300
SectorConsumer Defensive
Sector Strength42
IndustryTobacco
Share Statistics
EPS (TTM)0.90
Shares Outstanding24,607,792
10 Day Avg. Volume3,410
30 Day Avg. Volume3,300
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)0.40
Price to Sales (P/S)0.03
P/FCF Ratio-0.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pyxus International Business Overview & Revenue Model
Company Description
Pyxus International, Inc. operates as an agricultural enterprise, delivering specialized products and services to a diverse range of business and individual clients. A core part of its operations involves managing the entire supply chain for tobac...
How the Company Makes Money
Pyxus International makes money primarily by selling processed leaf tobacco to tobacco product manufacturers. Its revenue model is largely business-to-business and centers on (1) purchasing green tobacco leaf from growers (often in multiple origin...
Pyxus International Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call emphasized disciplined execution, improved cash generation, stronger rolling 12-month adjusted EBITDA, better leverage and liquidity, and progress on agricultural innovation. Near-term challenges include a notable year-over-year decline in quarterly sales, modest decreases in quarterly EBITDA and gross margin dollars, higher SG&A, a longer operating cycle, and outstanding long-term debt refinancing uncertainty. Management reiterated guidance and highlighted balance sheet improvement as a key focus.Positive Updates
Strong Start to Fiscal Year
Sales of $437.8M in Q1; performance described as a strong start and consistent with expectations, with management reaffirming full-year guidance.
Negative Updates
Quarterly Sales Decline
Sales declined to $437.8M from $508.8M year-over-year (down $71.0M, ~14.0%), driven by lower average costs and sales prices in Africa and South America and timing of North American shipments.
Read all updates
Q1-2027 Updates
Positive
Negative
Strong Start to Fiscal Year
Sales of $437.8M in Q1; performance described as a strong start and consistent with expectations, with management reaffirming full-year guidance.
Read all positive updates
Company Guidance
The company reaffirmed its full‑year fiscal 2027 guidance, saying shipment volumes should strengthen over the remaining nine months with a cadence broadly consistent with last year and the full‑year outlook unchanged; Q1 metrics cited included sales of $437.8M (vs $508.8M prior year), gross margin $61.4M (14.0% vs 12.9%) and gross profit per kilo $0.84 (vs $0.86), SG&A $43.9M, adjusted EBITDA $27.7M (rolling 12‑month adjusted EBITDA $225M vs $182.9M), inventory $1.1B, operating cycle 173 days (+13 days YoY), cash $175.9M with no ABL borrowings, notes payable down $52.4M YoY, rolling 12‑month adjusted free cash flow $123.4M and free cash flow adjusted for working capital $28M, leverage improved to 4.9x (from 6.8x) and interest coverage to 1.6x (from 1.4x), while management noted lower‑cost, slower purchasing in key sourcing regions and ongoing work to address upcoming long‑term debt maturities.Pyxus International Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
28
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34B | 2.41B | 2.48B | 2.03B | 1.91B | 1.64B |
| Gross Profit | 342.42M | 332.30M | 342.98M | 312.33M | 261.02M | 227.06M |
| EBITDA | 189.72M | 196.73M | 181.83M | 160.18M | 117.20M | 97.57M |
| Net Income | 23.11M | 14.57M | 15.17M | 2.66M | -56.75M | -92.00M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.69B | 1.50B | 1.66B | 1.58B | 1.70B |
| Cash, Cash Equivalents and Short-Term Investments | 175.91M | 134.34M | 78.25M | 92.57M | 136.73M | 198.78M |
| Total Debt | 1.32B | 963.82M | 877.99M | 1.05B | 1.04B | 1.10B |
| Total Liabilities | 1.84B | 1.51B | 1.34B | 1.51B | 1.44B | 1.52B |
| Stockholders Equity | 167.97M | 174.49M | 160.09M | 142.28M | 137.85M | 175.28M |
Cash Flow | ||||||
| Free Cash Flow | -94.83M | -230.50M | -36.41M | -236.01M | -154.13M | -213.59M |
| Operating Cash Flow | -72.87M | -208.45M | -13.39M | -214.97M | -137.82M | -198.76M |
| Investing Cash Flow | 208.37M | 191.42M | 170.64M | 159.45M | 154.94M | 181.24M |
| Financing Cash Flow | -53.49M | 72.52M | -167.26M | 25.56M | -83.00M | 123.26M |
Pyxus International Technical Analysis
Negative
3.13
Price Trends
3.37
Negative
3.11
Positive
3.10
Positive
Market Momentum
-0.08
Positive
43.13
Neutral
25.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYYX, the sentiment is Negative. The current price of 3.13 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 3.37, and above the 200-day MA of 3.10, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 43.13 is Neutral, neither overbought nor oversold. The STOCH value of 25.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PYYX.
Pyxus International Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $296.88B | 27.57 | -112.19% | 3.05% | 9.12% | 32.00% | |
69 Neutral | $121.06B | 14.14 | 13.38% | 5.32% | 4.47% | 117.22% | |
66 Neutral | $112.99B | 14.48 | -265.17% | 5.81% | 1.01% | -8.27% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $1.69B | 35.26 | 11.93% | 0.41% | 20.10% | -3.19% | |
51 Neutral | $1.14B | 60.18 | 1.33% | 6.12% | -3.04% | -81.53% | |
50 Neutral | $77.02M | 3.35 | -3.22% | ― | -0.56% | ― |
* Consumer Defensive Sector Average
PYYX
Pyxus International
3.13
-0.74
-19.12%
MO
Altria Group
68.65
5.71
9.07%
BTI
British American Tobacco
56.13
2.36
4.40%
PM
Philip Morris
191.89
30.60
18.97%
UVV
Universal
45.74
-6.82
-12.97%
TPB
Turning Point Brands
83.93
-15.24
-15.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.